Why did CRISPR Therapeutics stock fall pre-market?

CRISPR Therapeutics stock fell premarket after announcing plans to raise $350 million through a private offering of convertible senior notes. The notes are scheduled to mature in 2031. The company stated the funds will support ongoing research and development efforts. The debt securities will rank as senior unsecured obligations.